ASPET

OCTOBER 20, 2023

This study aimed to evaluate the effects of cytochrome P450 3A4 (CYP3A4) gene polymorphism and drug interaction on the metabolism of blonanserin. Human recombinant CYP3A4 was prepared using the Bac-to-Bac baculovirus expression system.

Pharmacogenetics 40

Pharmacogenetics Drugs 40

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Ataxia telangiectasia mutated (ATM) kinase is a key regulator of DSB repair, and ATM inhibitors are being explored as radiosensitizers for various tumors, including primary and metastatic brain tumors.

Pharmacokinetics 40

Pharmacokinetics Pharmacogenetics Treatment DNA 40

ASPET

OCTOBER 12, 2023

Achieving adequate exposure of a therapeutic agent at the target is a critical determinant of efficacious chemotherapy. With this in mind, a major challenge in developing therapies for central nervous system (CNS) tumors is to overcome barriers to delivery, including the blood-brain barrier (BBB).

Pharmacogenetics 40

Pharmacogenetics Clinical Trials Treatment Therapies 40

ASPET

AUGUST 4, 2023

Neuroblastoma (NB) is a pediatric cancer with low survival rates in high-risk patients. 131 I-mIBG has emerged as a promising therapy for high-risk NB and kills tumor cells by radiation. Consequently, 131 I-mIBG tumor uptake and retention are major determinants for its therapeutic efficacy.

Pharmacogenetics 40

Pharmacogenetics Therapies Disease 40

ASPET

JANUARY 31, 2024

We recently showed that riboflavin is a selected substrate of BCRP over P-gp and demonstrated its prediction performance in preclinical DDI studies. The aim of this study was to investigate the suitability of riboflavin to assess BCRP inhibition in humans.

Pharmacogenetics 40

Pharmacogenetics Pharmacokinetics Drug Development Drugs 40

Drug Discovery World

OCTOBER 5, 2022

This is where personalised drug screening and personalised treatment comes in because we can map pharmacogenetics, toxicity and drug metabolism of the active pharmaceutical ingredient for the particular individual. . Conventional drug discovery is a cumbersome process, as there are lots of stages to be tested with.

Pharmacogenetics 130

Pharmacogenetics Regulations Drugs Therapies 130

ASPET

NOVEMBER 17, 2023

Creatinine, a clinical marker for kidney function, is predominantly cleared by glomerular filtration, with active tubular secretion contributing to about 30% of its renal clearance.

Pharmacogenetics 40

Pharmacogenetics Pharmacokinetics Disease Drugs 40

The Pharma Data

OCTOBER 27, 2020

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology.

Pharmacogenetics 40

Pharmacogenetics Laboratories Therapies Hospitals 40

Drug Discovery World

OCTOBER 25, 2023

We can use NGS to better understand so-called “pharmacogenetics” so that we can predict how an individual may respond to a given treatment. This largely relates to the first question when I talked about pharmacogenetics and revealing and targeting specific mutations in an individual’s tumour. DG : For sure!

Bioinformatics 287

Bioinformatics Pharmacogenetics RNA Medical Schools 287

ASPET

MARCH 6, 2024

The organic anion transporting polypeptide (OATP) 2B1 (gene name SLCO2B1 ) is an uptake transporter that facilitates cellular accumulation of its substrates. In order to assess the in vivo relevance of the transporter, we applied SLCO2B1 +/+ knock-in and Slco2b1 -/- knock-out rats.

Protein Expression 40

Protein Expression Pharmacogenetics Treatment Drugs 40

ASPET

AUGUST 4, 2023

The natural product goldenseal is a clinical inhibitor of CYP3A activity, as evidenced by a 40-60% increase in midazolam AUC after coadministration with goldenseal. The predominant goldenseal alkaloids berberine and (-)-β-hydrastine were previously identified as time-dependent CYP3A inhibitors using human liver microsomes.

Pharmacokinetics 40

Pharmacokinetics Pharmacogenetics Production Drugs 40

The Pharma Data

OCTOBER 27, 2020

The system is a highly sensitive, cost-effective, mass spectrometry-based platform for high-throughput genetic analysis and is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics, agricultural genomics, and clinical research.

Pharmacogenetics 52

Pharmacogenetics Laboratories Clinical Research FDA 52